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Abstract 
Conventional immediate release dosage forms involve compressing the powder with a 
disintegrating agent that enables rapid disintegration and dissolution upon oral ingestion. 
Among 3D printing technologies, the fused deposition modelling (FDM) 3D printing 
technique has considerable potential for patient-specific dosage form. However, the use of 
FDM 3D printing in tablet manufacturing requires large portion of polymer, which slows 
down drug release through erosion and diffusion mechanisms. In this study, we demonstrate 
for the first time the use of a novel design approach of caplets with perforating channels to 
accelerate drug release from 3D printed tablets. This strategy has been implemented using a 
caplet design with perforating channels of increasing width (0.2, 0.4, 0.6, 0.8 or 1.0 mm) and 
variable length, and alignment (parallel or at right angle to tablet long axis). 
Hydrochlorothiazide (BCS class IV drug) was chosen as model drug as enhanced dissolution 
rate is vital to guarantee oral bioavailability. The inclusion of channels exhibited an increase 
in the surface are/volume ratio, however, the release pattern was also influenced by the width 
and the length of the channel. A channel width ≥0.6 mm deemed critical to meet the USP 
criteria of immediate release products. Shorter multiple channels (8.6 mm) were more 
efficient at accelerating drug release than longer channels (18.2 mm) despite having 
comparable surface area/mass ratio. This behaviour may be linked to the reduced flow 
resistance within the channels and the faster fragmentation during dissolution of these tablets. 
In conclusion, the width and length of the channel should be carefully considered in addition 
to surface area/mass when optimizing drug release from 3D printed designs. The 
incorporation of short channels can be adopted in the designs of dosage forms, implants or 
stents to enhance the release rate of eluting drug from rich polymeric structures. 
 
Keywords: Patient-centred; bespoke, Personalised; Patient-specific; additive 
manufacturing, complex geometry 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
1. Introduction  
Immediate release tablets is the most commonly used dosage form [1, 2]. This trend is likely 
to continue in oral drug delivery. Between 2005-2015, 79% of new drug approvals (NDAs) 
for oral products were for immediate release formulations [3]. In fact, accelerating drug 
release from tablet has been highly desirable in oral formulations for the last few decades. 
Several advancements were introduced to accelerate tablet disintegration and dissolution such 
as super-disintegrants [4-6], effervescent [7-9] and alkaline solubiliser [10].  
The first patent for compressed tablets was filed in 1843 in England in an effort to form a pill 
without using a large amount of binder that slows drug release [11]. The compressing powder 
under high pressure has since become the standard method for tablet manufacturing. The 
formulation design of tablets has been well-established for decades using common 
ingredients such as filler, binder, a gliding and disintegrant as well as a material that allow 
fast disintegration in the gastric environment. Later, between 1930s-1950s, in order to 
improve palatability, ecstatic quality and patient compliance, film coatings were introduced 
[12].  
The principal mechanism of tablet formation remained the same until the introduction of 
powder based 3D printing technology, where the use of powder bed allows the binding of 
powders in situ to form tablets [13]. However, this has been at the expense of the ecstatic and 
mechanical properties of these tablets, with poor finishing, rough surface [14] and high 
friability value [15, 16]. Recently, fused deposition modelling (FDM) 3D printing has been 
proposed as an alternative 3D printing technology for on demand fabrication of 
individualised dosage forms [17, 18] and offered several advantages. It is a low cost 
production unit with minimal space requirements and produces mechanically resistant tablets 
without the need to a finishing step [17-20].  
Unlike conventionally compressed tablets, where dissolution is first initiated by tablet 
disintegration after water imbibition and particle swelling, the disintegration and dissolution 
of FDM 3D printed tablets may be dominated by erosion and diffusion mechanisms [17, 18]. 
This is resulted by the use of a high percentage of polymer for filament production in hot 
melt extrusion HME (minimum polymer loading of 45% w/w) [21]. Such polymer-rich 
structure has a significant effect on slowing drug release from the fabricated tablets. This 
might be reflected in numerous examples for extended drug release [18, 22-27]. It is the 
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immediate release that is the most challenging to achieve from FDM 3D printed structures 
[28, 29]. 
 
Previous attempts investigated the effect of the external shape and volume/mass ratio of 3D 
printed tablets on the pattern of extended drug release [30]. Some efforts also exploited the 
infill function of FDM [17, 31], and inkjet [31] 3D printers to modify drug release. However, 
this approach was originally introduced to 3D printing to enhance the structural integrity of 
the printed object while minimizing the use of material. It necessitated the dissolution of the 
shells before media penetration and often yielded low-density floating tablets. In order to 
accelerate drug release from FDM 3D printed structures, an alternative solution for tablet 
disintegration and dissolution is essential.  
In this research, we have introduced a novel tablet design with built-in channels to accelerate 
drug release from 3D printed polymethacylate tablets. The impact of channel width, length 
and position on in vitro drug release has been investigated in addition to surface area/volume 
ratio. This work also uniquely investigated the impact of such design on changes in 3D 
printing objects throughout the dissolution process and compared this solution to the 
traditional conventional approach of adding disintegrant. Hydrochlorothiazide, a 
biopharmaceutical classification system (BCS) class IV drug with poor solubility and 
permeability [32-34], was chosen as model drug as accelerating drug release is essential to 
maintain oral bioavailability. 
2. Materials and methods 
 
2.1 Materials 
Hydrochlorothiazide (HCT) (Tm=268°C), triethyl citrate (TEC) and tri-Calcium phosphate 
(TCP) were supplied by Sigma-Aldrich (UK). Eudragit E was donated by Evonik Industries 
(Darmstadt, Germany). Croscarmellose sodium (Ac-Di-Sol® and Primellose®) was supplied 
by FMC Biopolymer (USA) and DFE Pharma (Germany) respectively, sodium starch 
glycolate (Primojel® and Explotab®) were donated by DFE Pharma (Germany) and JRS 
pharma LP (USA) respectively, crosslinked polyvinylpyrrolidone (Polyplasdone-XL®) was 
donated by Ashland (USA). Scotch Blue Painter’s tape 50 mm was supplied by 3M 
(Bracknell, UK). All other agents were provided by Sigma Aldrich (UK). 
2.2 Preparation and optimisation of filaments.  
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An optimised ratio of Eudragit E: TEC: TCP: HCT (46.75:3.25:37.5:12.5 %wt) was 
employed to produce drug loaded filaments [29]. Approximately 10 g of materials was 
accurately weighed and added gradually to counter flow twin-screw hot melt extruder, 
HAAKE MiniCTW (Karlsruhe, Germany). To allow homogeneous distribution of the 
powders, the molten mass was mixed in the extruder for at least 5 min prior to extrusion. The 
specific temperatures of initial feeding and extrusion for the filament were 100 and 90°C 
respectively. A torque control of 0.8 Nm was used to extrude out the filaments. Filaments 
were stored in sealed plastic bags at room temperature before 3D printing.  
For disintegrant containing filament, a ratio of Eudragit E: TEC: TCP: disintegrant: HCT 
46.75:3.25:33.5:4:12.5 were used to produce individual filaments for each of the following 
disintegrants: Ac-Di-Sol®, Primellose®, Primojel®, Polyplasdone-XL® or Explotab® 
2.3 Design and printing of tablets. 
The basic shape of the tablet is based on capsule-shaped tablet (caplet) design at dimensions: 
17.2 x 6.8 x 6.25mm. In order to assess the impact of tablet volume, a series of tablets of 
increasing tablet dimensions were designed and printed (Tablet 1). The caplet design 
(dimensions: 17.2 x 6.8 x 6.25mm) was perforated with identical channels of square section 
and rectangular length. The widths of channel section were 0.2, 0.4, 0.6, 0.8 or 1.0 mm. The 
impact of the length and orientation of the channels within the caplet design was investigated 
by applying either a) 9-long channel parallel to the long axis of the caplet design or b) 18-
shorter channels at right angle to the long axis of the caplet design (Figure 2). As it was not 
possible to include these channels and maintain identical surface/volume ratio without 
fundamentally altering tablet dimensions and shape, the dimensions of the channelled tablet 
design were kept identical and the changes in surface area and surface to volume ratio was 
reported in Table 2.  
Tablets were constructed with the pre-prepared filaments using a commercial FDM 3D 
printer with a 0.4mm nozzle. The templates used to print the tablets were designed in caplet 
shape using Autodesk® 3ds Max-Design 2016 software version 18.0 (Autodesk, Inc., USA). 
The design was saved in a stereolithography (.stl) file format and imported to the 3D printer’s 
software, MakerWare Version 2.4.0.17 (Makerbot Industries, LLC. USA). Tablets were 
printed using modified settings of the software for PLA filament as described in our previous 
work.[21] The temperature for 3D printing and build plate was 135°C and 60°C respectively 
and at standard resolution. As the density of the printed structure is dependant of the density 
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of extruded filament and the voids between the fused filaments layers (above and beyond the 
channels space of the original design), it is important to maintain the same filling pattern 
across the different designs. Therefore, the settings of the slicing engine (infill pattern = 
hexagonal, infill density=100%, layer height = 200µm) were identical for all printed designs. 
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Table 1 Measured dimensions, volumes, surface area, surface to volume and surface to mass ratios 
of CAD designs of solid tablets (no channels). 
   
Tablet Dimensions Volum
e of 
CAD 
design 
(mm
3
) 
Mass 
of 
printe
d 
caplet
s 
(mg) 
Surfac
e area 
of CAD 
design 
(mm
2
) 
Surface/volum
e 
ratio of CAD 
design (mm
-1
) 
 
CAD 
Surface/Printe
d mass 
(mm
2
/mg) 
X  
(mm) 
Y  
(mm) 
Z 
(mm) 
Tablet
-6mm 
6.22±0.1 2.16±0.0
6 
2.08±0.0
6 
23.57 30.84 
+ 4.16 
46.05 2.0 1.49 
Tablet
-9mm 
8.72±0.26 3.36±0.1
3 
3.14±0.0
9 
79.54 110.93 
+4.43 
103.62 1.3 0.93 
Tablet
-
12mm 
11.42±0.0
6 
4.61±0.5 4.84±0.1
6 
188.66 211.8 
+ 0.71 
184.21 1.0 0.87 
Tablet
-
14mm 
13.88±0.2 6.07±0.0
4 
5.27±0.1
1 
299.43 405.53 
+16.21 
250.74 0.8 0.62 
Tablet
-
16mm 
16.02±0.3
8 
6.98±0.1
3 
6.15±0.1 446.97 535.35 
+ 4.29 
327.5 0.73 0.61 
Tablet
-
18mm 
17.29±0.3
4 
6.85±0.0
6 
6.09±0.0
5 
636.4 785.73 
+ 1.44  
414.49 0.65 0.53 
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Table 2. Measured dimensions, volumes, surface area, surface to volume and surface to mass ratios 
of CAD designs of solid and channelled tablets 
Tablet 
design 
Dimensions Channel  
dimensio
ns in CAD 
design 
(mm) 
Volum
e of 
CAD 
desig
n 
(mm 3) 
Mass 
of 
printe
d 
caplet
s 
(mg) 
Surfac
e area 
of 
CAD 
design 
(mm 2) 
Surface/volu
me 
ratio of CAD 
design 
(mm -1) 
CAD 
Surface/Print
ed mass 
(mm 2/mg) 
X 
(mm) 
Y 
(mm) 
Z 
(mm) 
Solid 
design 
(no 
channel
s) 
16.99±0.1 6.79±0.0
1 
6.09±0.0
5 
No 
channels 
553.81 785.73 
+ 1.44 
377.8 0.682 0.481 
9 
channel
s 
(0.2mm) 
17.07±0.1
2 
6.51±0.0
6 
5.9±0.02 0.2x0.2 548.02 593 + 
7.90 
493.34 0.9 0.832 
9 
channel
s 
(0.4mm) 
16.89±0.0
3 
6.53±0.0
6 
5.9±0.06 0.4x0.4 530.46 579.33 
+ 6.54 
607.59 1.15 1.049 
9 
channel
s 
(0.6mm) 
16.86±0.0
6 
6.7±0.07 6.07±0.3
5 
0.6x0.6 501.38 591 + 
5.72 
718.64 1.43 1.216 
9 
channel
s 
(0.8mm) 
16.78±0.0
8 
6.78±0.0
3 
5.9±0.02 0.8x0.8 460.95 571.33 
+ 0.53 
825.89 1.79 1.446 
9 
channel
s (1mm) 
16.78±0.1
4 
6.63±0.1
1 
6.0±0.09 1 x 1 408.25 546.67 
+ 4.89 
934.75 2.29 1.710 
18 
channel
s 
(0.2mm) 
16.98±0.0
9 
6.52±0.0
2 
6.0±0.12 0.2 x 0.2 549.07 552 + 
3.62 
471.19 0.86 0.854 
18 
channel
s 
(0.4mm) 
16.97±0.0
2 
6.66±0.0
1 
5.9±0.04 0.4 x 0.4 534.81 639.33 
+ 1.54 
561.53 1.05 0.878 
18 
channel
16.96±0.0
7 
6.65±0.0
4 
6.1±0.05 0.6 x 0.6 511.19 604 + 
1.79 
647.5 1.27 1.072 
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2.4 Thermal analysis. 
Samples (raw materials, extruded filaments and printed tablets) were characterised using 
differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). For DSC 
analysis, a differential scanning calorimeter DSC Q2000 (TA Instruments, Elstree, 
Hertfordshire, UK) with a heating rate of 10 °C/min was used. Samples were first cooled to 
−50 °C followed by an isotherm for 1 minute and then heat scan from −50 to 300 °C. 
Analysis was carried out under a nitrogen (50 mL/min) purge. The data was analysed using 
TA 2000 analysis software. Tzero TA aluminium pans and Tzero hermetic lids were used 
with an approximate sample mass of 7 mg. All measurements were carried out in triplicates. 
For TGA analysis, raw materials, model drug, extruded filaments and 3D printed tablets were 
measured using a TGA Q500 (TA Instruments, Elstree, Hertfordshire, UK). Samples (7 mg) 
were placed in 40 µL aluminium pans and then heated from 25 to 500 ̊C using a heating rate 
of 10°C/min. The thermal decomposition (or degradation) profile was analysed using TA 
2000 analysis software. The experiments were carried out under nitrogen gas flow of 
50 mL/min. All measurements were carried out in triplicates. 
2.5 X-ray Powder diffractometry (XPRD).  
A powder X-ray diffractometer, D2 Phaser with Lynxeye (Bruker, Germany) was used to 
assess the physical form of model drugs in Eudragit E, TCP, Eudragit E:TEC filament, blank 
and drug-loaded filaments, and 3D printed tablets. Samples were scanned from 2Theta= 5° to 
50° using 0.01° step width and a 1 second time count. The divergence slit was 1 mm and the 
scatter slit 0.6 mm. The wavelength of the X-ray was 0.154 nm using Cu source and a voltage 
s 
(0.6mm) 
18 
channel
s 
(0.8mm) 
16.89±0.0
8 
6.6±0.08 6.2±0.02 0.8 x 0.8 478.44 547.33 
+ 2.77 
728.17 1.52 1.330 
18 
channel
s (1mm) 
16.68±0.0
7 
6.6±0.02 6.21±0.1 1 x 1 436.91 540.67 
+ 
11.21 
802.4 1.84 1.484 
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of 30 kV. Filament emission was 10 mA using a scan type coupled with a two theta/theta 
scintillation counter over 30 min.  
2.6 Scanning Electron Microscopy 
The surface morphology of the filaments and the printed tablets was assessed using a Quanta-
200 SEM microscope at 20 kV. All samples for SEM visualisation were placed on a metallic 
stub and gold plated using a JFC-1200 Fine Coater (Jeol, Tokyo, Japan). Photographs of the 
tablets were captured with a Canon EOS-1D Mark IV (Canon Ltd, Japan). 
2.7 X-ray micro-computed tomography (XμCT) 
A SkyScan1172 high-resolution X-ray micro computed tomography (XμCT) scanner 
(Bruker-microCT, Belgium) was utilized to analyse the internal structure of the channelled 
tablet.  
2.8 Characterisation of the tablets properties 
In order to assess the impact of channelled design on the mechanical properties of the tablets, 
20 tablets were randomly selected, weighed and placed in a friability Tester Erweka type 
TAR 10 (Erweka GmbH, Heusenstamm, Germany) and the drum was then rotated at 25 rpm 
for 4 min. The tablets were reweighed and the differences in weight were calculated and 
displayed as a percentage of the original sample weight. Drug contents in the samples were 
assessed using an Agilent UV-HPLC 1260 series (Agilent Technologies, Inc., Germany) 
equipped with Kinetex C18 column (100 × 2.1 mm, particle size 2.6 μm) (Phenomenex, 
Torrance, USA). The mobile phase was (acetonitrile: water adjusted pH 3 with 
orthophosphoric acid) at ratio 70:30 and a flow rate of 0.5 mL/min. The injection volume was 
20 µL and stop time was 5 min per sample. The wavelength was set to 230nm at 37° C and 
retention time of the drug was 2.75 min.  The method showed linearity between 1-100mg/L 
with R2 = 0.996 and limits of detection and quantification of 0.1 and 2.5 mg/L respectively. 
The accuracy was 107.1%±5.1 and 97%±0.5 at concentrations: 12.5 and 37.5 mg/L 
respectively. 
2.9 In vitro Dissolution test of the tablets 
Drug release studies carried out using a USP II Erweka DT600 dissolution tester (Erweka 
GmbH, Heusenstamm, Germany). Three tablets were randomly selected and individually 
placed in the dissolution vessels each containing 900 mL of 0.1M HCl at 50 rpm and 37±0.5 
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◦C. Aliquots (4 mL) were manually collected using 5ml Leur-Lock syringes at 0, 5, 10, 15, 
20, 25, 30, 40, 50 and 60 minutes time intervals and filtered through a Millex-HA 0.45 µm 
filter. Each aliquot withdrawn was replaced with 4 mL of 0.1M HCl. The absorbance of 
hydrochlorothiazide was finally measured using a Jenway UV spectrophotometer (Bibby 
Scientific Ltd, UK) at λmax of 278 nm. All dissolution test were carried out in triplicates. In 
order to assess the disintegration behaviour of the 3D printed tablet during dissolution test, 
the dissolution test has been video recorded using a Sony HXR-NX3 camera (Sony 
Electronics Inc., Japan) with the macro option on. Wide-angle green laser probes were used 
to illuminate the tablets during dissolution in a dark room. All dissolution test were carried 
out under sink condition [35]. 
 
2.10 Statistical analysis 
One-way ANOVA was employed using SPSS Software (22.0.0.2) to analyse the differences 
in the percentages of drug release at T=30 min. Differences in results between p≤ 0.05 were 
considered significant, p of 0.05 was considered not significant. 
 
3. Results and discussion 
Thiazide diuretic methacrylate tablets were produced using FDM 3D printing using Eudragit 
E based filament as the feed ink. Thermal analysis indicated that the filament is stable at the 
preparation temperature (Figure S1a) and flexible with a Tg of 29.5 oC (Figure S1b). X-ray 
diffraction spectra (Figure S1c) confirmed that a portion of hydrochlorothiazide was 
crystalline with the appearance of peak at 2Theta = 19.15o and 28.7o [36]. 
The poly-methacrylate tablets with a solid design (no channels) and increasing tablet volume 
were 3D printed. The USP dissolution result illustrated that the drug release rate slowed 
down with increased volume (Figure 1a, Table 1). This may be due to the reduced 
surface/mass ratio of the larger tablets. As drug release from polymeric matrix is mainly 
governed by erosion and diffusion mechanism [37-39], a slower release was expected due to 
the smaller surface area/mass ratio.  
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Figure 1. Impact of caplet dimensions and inclusion of disintegrant on in vitro drug release from 3D 
printed tablets (solid design). a) In vitro release of hydrochlorothiazide from different sizes of Eudragit 
E tablets, the percentages of drug release at T=30 min were considered as functionality outcome, one 
way ANOVA, P<0.05 (mean ± SD, n=3), b) in vitro release of hydrochlorothiazide from Eudragit E 
caplets with/without commercially available disintegrants (mean ± SD, n=3).   
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
An established approach to accelerate drug release from tablet is through the incorporation of 
a disintegrant. Different disintegrants were added in the tablet formation; however, they 
seemed to add little to accelerating drug release (Figure 1b). With their porous structure, 
disintegrants function by increasing water uptake into the tablet and elevating the internal 
pressure trough swelling [40, 41]. The inability of the disintegrant to induce tablet 
disintegration and in turn to accelerate drug release may be due to the relatively excessive 
percentage of the polymer in the tablet matrix. During the thermal processing of HME, it is 
possible that the liquefied polymer has coated the disintegrant particles, sealed their pores and 
restricted their swelling during dissolution test. Further increase in disintegrant resulted in a 
difficult-to-print filament and did not favour dissolution (unpublished work). 
 
A schematic diagram of design of 3D printed tablet with built-in channels is shown in Figure 
2. Tablets were crafted in an easy-to-swallow caplet design. In order to accelerate drug 
release, the design has been perforated with square channels of increasing widths. Two 
orientations of the channels were proposed either parallel to the caplet’s long axis or at right 
angle to the axis. In order to maintain a comparable surface/volume ratios, a larger number of 
shorter channels were incorporated.  
 
The images of rendered tablet designs and photos of actual tablet with increasing built-in 
channels are shown in Figure 3. The printed structures maintained their shape, form and 
structure. The tablet remained mechanically resistant with a friability value of zero, hence 
indicating that the inclusion of channels did not alter the product’s suitably to handle and 
swallow. 
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Figure 2. Schematic illustration concept of perforating square sectioned channels. The dissolution 
medium will perforate through the channels and accelerate tablet disintegration and dissolution. The 
perforating channels were a1) parallel to long axis (9 long channels) or b1) at right angle with the long 
axis with 3D max rendered images of frontal, side and top view of channelled tablet designs. 
 
Figure 3. Rendered images of tablet designs with decreasing channel size with a) 9-long channels b) 
18-short channels, photographs of tablets with decreasing channel size c) 9 long channels d) 18 short 
channels.  
In order to gain a better understanding of the internal structure of the tablets, XµCT technique 
was employed (Figures 4-5). For 1.2 mm channelled tablet, it is evident that the channel 
height is made of 5 channels each is 200 µm high. The upper surface of each channel within 
the tablet showed some downward facing curvatures and bends as opposed to the lowed 
surface. This deformation might be related to the absence of the support for the weight of this 
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area during the solidification of the fusing layers. Such a deformation is also noted when 18-
short short channels were 3D printed.  
 
Figure 4. Visualisation of XμCT data of 9-long channel design with 1 mm channel. View of the 
internal structure of the internal surface of the channel from (a) bottom and (b) top, c) X-Y section 
and d) Y-Z section of the long channels across the tablets.  
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Figure 5. Visualisation of XμCT data of 18-short channel design with 1 mm channels. a) Side view 
of the tablet, b) view of the top, c) X-Y section and d) X-Z section of the channels across the 
tablets.  
 
The impact of design on in vitro drug release from the constructed tablet showed slow release 
from block tablets (Figure 6). When short channels of 0.2-0.4 mm channel were used, a 
limited improvement of dissolution rate was noticed. However, increasing the channel width 
to 0.8-1.0 mm led to a significant increase in theophylline release at T=30 min, reaching 
78.7%, 88.5% and 92.3% for 9-long channel design, and 85%, 93.4% and 93.4% for 18-short 
channelled design. It is important to highlight that such an increase in percentage of drug 
release with channelled tablets was critical to meet pharmacopeial criteria of immediate 
release tablets. 
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Figure 6. Impact on channel width and orientation on dissolution release pattern from 
hydrochlorothiazide methacrylate tablet in USP II dissolution test in gastric medium (0.1 M HCl pH 
1.2, 50 rpm. Average ±SD) a) 18 long tablets, and b) short tablets.  
Several literature reports directly linked the increase in dissolution rate to an increase in the 
total surface area in multi-units [42-44] and 3D printed tablets [30]. It was expected that in 
vitro hydrochlorothiazide release was directly related to surface area/volume. However, the 
length of the channel appeared to have a significant effect on the extent of drug release. For 
instance, the use of 18-short channels has been more effective in increasing in vitro drug 
release at T=30 min compared to the 9-long channel design despite having significantly lower 
surface/volume ratio (Table 2). Wide-angle green light imaging of the first 10 min of the 
dissolution test confirms the surface erosion of 3D printed tablet during dissolution test in 
both channel designs (Figure 7). The imaging confirmed a faster erosion from 18-short 
channels design in comparison to 9-channels (44.3% versus 38.3% after T=10 min) (p<0.05). 
Previous attempts to modify the internal structure of 3D printed tablets by modifying the 
infill percentage [17, 22, 45]. This led to formation of a low density and floating tablets, 
where the penetration of aqueous medium takes place in a chamber by chamber order. In 
contrast, the proposed channelled approach allowed the tablet to be immerged in the medium 
while preserving an easy-to-swallow structure. 
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Figure 7.  Wide-angle green light imaging during the first 10 min of USP II dissolution test of 3D 
printed hydrochlorothiazide tablets with a) solid design, b) long 9 channel design and c) 18 short 
channel design using mono-colour laser light  
The changes in the shape of the channelled tablets during dissolution process have also been 
monitored at 5 min intervals (Figure 8). Both tablet designs showed an expansion in the 
width of the channels during the dissolution process with a progressing decrease in the 
thickness of inter-channel walls. This has been accompanied by a loss in the square shape of 
the channel section and the formation of more rounded sections. As the inner diameter of the 
channel increased, the inter-channel spaces became narrower leading to the fragmentation of 
the tablet into smaller fractions in the dissolution medium. Such effect is more pronounced in 
the designs of shorter channels, where inter-channel domains are shorter (Figure 8c).  
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Figure 8. Impact of tablet design and channel length on the erosion pattern of 3D printed tablets. 
Photograph of 3D printed tablets before and after 5, 10, 15, 20, 25 and 30 min of undertaking USP II 
dissolution test in gastric medium (pH 1.2) with a) solid design, b) long 9 channel design and c) 18 
short channel designs. 
An important factor that impact the pattern of drug release is the flow of gastric medium 
through the channels during the dissolution process. The area within channel of L length and 
W width can be expressed as 4WL. If ƞ is viscosity of dissolution medium, the force needed 
to drive the pressure force within the channel. The velocity gradient will be expressed as  
𝑑𝑣
𝑑𝑤
 
and the pressure force applied to move the channel is ρ  
And the viscosity force will be -ƞ 
𝑑𝑣
𝑑𝑤
 4WL  
 
ρ w2 = -ƞ 
𝑑𝑣
𝑑𝑤
 4WL 
 
The longer the channel the higher the hydraulic forces needed to allow drug flow. 
However, the significant reduction in the length of the channel in tablets with shorter channel 
reduces the friction surface area leading to a faster flow of the medium. It is also important to 
highlight that with erosion of methacrylate matrix, the width of the channel, W will be 
increased, leading to a reduction in the resistance to flow and accelerating the flow rate, 
hence leading to a faster drug release.  It is also worth noting that channelling system is more 
suitable to non-swelling systems as a swellable polymer matrix might lead to narrowing or 
closure of channels upon introduction to aqueous medium.  
 
In summary, this work clearly demonstrated the potential of channelled system in modifying 
the release and fragmentation pattern of FDM 3D printed tablets. With development of novel 
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materials and significant improvement in the resolution and accuracy of future 3D printing 
technologies [46], we anticipate that CAD will allow production of more detailed structures 
with different mechanical and drug release functionality from established polymeric 
matrices.. 
 
4. Conclusions 
We have presented an alternative novel design approach through engineering perforating 
channels within the tablet design. This complex structure design does not only increase the 
surface area of the tablet, but also facilitate media perforation through the structure. A 
channel size of ≥0.6mm is essential to accelerate the drug release and meet pharmacopeial 
criterion for immediate release products. The use of large number of shorter channels proved 
more efficient in accelerating drug release from the tablet than longer channels. This has been 
attributed to the reduced resistance to flow and faster fragmentation of the tablet of shorter 
channels during dissolution test. The incorporation of short channels can be adopted in the 
designs of dosage forms, implants or stents to enhance the release rate of eluting drug from 
rich polymeric structures. It is anticipated that a new generation of dosage form of complex 
geometry will emerge to tailor drug release via controlling the media flow through these 
built-in channels. 
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printed hydrochlorothiazide tablets with a) solid design, b) long 9 channel design and c) 18 
short channel design using mono-colour laser light  
Figure 8. Impact of tablet design and channel length on the erosion pattern of 3D printed 
tablets. Photograph of 3D printed tablets before and after 5, 10, 15, 20, 25 and 30 min of 
undertaking USP II dissolution test in gastric medium (pH 1.2) with a) solid design, b) long 9 
channel design and c) 18 short channel designs. 
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